We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+4.78%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$599M
AUM Growth
+$24.9M
Cap. Flow
+$44M
Cap. Flow %
7.35%
Top 10 Hldgs %
69.44%
Holding
34
New
7
Increased
17
Reduced
7
Closed
2

Top Buys

Rank Stock Value
1
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$21.8M
2
GBT
Global Blood Therapeutics, Inc.
GBT
+$21.5M
3
ACHN
Achillion Pharmaceuticals
ACHN
+$20.7M
4
EW icon
Edwards Lifesciences
EW
+$13.5M
5
PTCT icon
PTC Therapeutics
PTCT
+$10.7M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$33.2M
2
AVXS
AveXis, Inc. Common Stock
AVXS
+$18.7M
3
BLUE
bluebird bio
BLUE
+$14.3M
4
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$9.62M
5
FSTX
F-star Therapeutics, Inc. Common Stock
FSTX
+$4.2M

Sector Composition

Rank Sector Weight
1 Healthcare 90.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTCT icon
1
PTC Therapeutics
PTCT
$6.37B
$68.9M 11.5%
4,130,115
+634,972
+18% +$10.7M
RGNX icon
2
Regenxbio
RGNX
$623M
$51.9M 8.66%
1,561,210
+22,205
+1% +$669K
BMY icon
3
Bristol-Myers Squibb
BMY
$127B
$51.4M 8.59%
839,452
+11,940
+1% +$747K
ALNY icon
4
Alnylam Pharmaceuticals
ALNY
$36.3B
$45.6M 7.61%
358,774
-264,564
-42% -$33.2M
DRNA
5
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$44.1M 7.37%
5,035,662
+2,956,671
+142% +$21.8M
ACHN
6
DELISTED
Achillion Pharmaceuticals
ACHN
$39M 6.51%
13,546,902
+5,707,136
+73% +$20.7M
LJPC
7
DELISTED
La Jolla Pharmaceutical Company
LJPC
$34.2M 5.71%
1,063,170
+18,863
+2% +$616K
AVXS
8
DELISTED
AveXis, Inc. Common Stock
AVXS
$31.1M 5.2%
281,242
-186,425
-40% -$18.7M
ABUS icon
9
Arbutus Biopharma
ABUS
$865M
$26M 4.34%
5,151,615
-114,665
-2% -$672K
GBT
10
DELISTED
Global Blood Therapeutics, Inc.
GBT
$23.7M 3.95%
601,683
+575,373
+2,187% +$21.5M
OSUR icon
11
OraSure Technologies
OSUR
$273M
$16.6M 2.77%
878,452
+342,745
+64% +$6.21M
BCRX icon
12
BioCryst Pharmaceuticals
BCRX
$2.37B
$16.6M 2.76%
3,372,674
+47,969
+1% +$232K
CORI
13
DELISTED
Corium International, Inc.
CORI
$16.3M 2.73%
1,699,653
+24,174
+1% +$258K
AGEN
14
Agenus
AGEN
$249M
$14.1M 2.36%
220,604
+5,670
+3% +$433K
EW icon
15
Edwards Lifesciences
EW
$47.6B
$13.9M 2.31%
+369,000
New +$13.5M
VRAY
16
DELISTED
ViewRay, Inc.
VRAY
$12.5M 2.08%
1,348,210
+327,748
+32% +$2.62M
MYOK
17
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$10.8M 1.81%
257,663
+3,701
+1% +$143K
MASI
18
DELISTED
Masimo
MASI
$10.3M 1.71%
120,900
– –
ATRA icon
19
Atara Biotherapeutics
ATRA
$71.2M
$10.1M 1.68%
22,245
-3,996
-15% -$1.48M
KA
20
DELISTED
Kineta, Inc. Common Stock
KA
$8.74M 1.46%
+10,714
New +$4.11M
VIVE
21
DELISTED
VIVEVE MED INC
VIVE
$8.31M 1.39%
1,673
+200
+14% +$1.04M
QURE icon
22
uniQure
QURE
$2.68B
$7.91M 1.32%
+403,524
New +$6.14M
VCEL icon
23
Vericel Corp
VCEL
$2.3B
$7.11M 1.19%
+1,304,801
New +$6.02M
ODT
24
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$6.77M 1.13%
+297,555
New +$7.03M
TCMD icon
25
Tactile Systems Technology
TCMD
$620M
$6.1M 1.02%
210,366
-142,850
-40% -$4.14M
1
2

Similar funds

MG
Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OAM
OP Asset Management Helsinki $9.95B AUM 30.22% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RTW Investments's Q4 2017 Portfolio in Review

As of Q4 2017, RTW Investments held 34 positions worth $599M, up 4.3% from $574M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

RTW Investments deployed $44M of net new capital in Q4 2017, opening 7 new positions and adding to 17 existing holdings. Its largest new stake was Edwards Lifesciences: 369,000 shares worth $13.9M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 97% a quarter earlier.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $33.2M trimmed.

  • RTW Investments's largest Q4 2017 buy was Edwards Lifesciences: 369,000 shares worth $13.9M.
  • RTW Investments added most to Dicerna Pharmaceuticals, Inc. in Q4 2017, an estimated $21.8M increase.
  • RTW Investments's biggest Q4 2017 reduction was Alnylam Pharmaceuticals, cutting an estimated $33.2M.
  • RTW Investments fully exited bluebird bio in Q4 2017, selling an estimated $14.3M.
  • RTW Investments's ten largest holdings make up 69% of its $599M portfolio in Q4 2017.
  • RTW Investments opened 7 new positions and closed 2 in Q4 2017.
  • RTW Investments's portfolio value rose 4.3% quarter-over-quarter to $599M.

Based on RTW Investments's 13F filing for Q4 2017, filed 14 Feb 2018.